-+ 0.00%
-+ 0.00%
-+ 0.00%

BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed

Benzinga·09/30/2026 20:22:53
語音播報

https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm